Product Program year 2024 Source: CMS Open Payments

Arexvy

Drug Respiratory

NDC 58160-848-11

Open in the dashboard

General payments

$12,525,608

192,195 payments

Research payments

$0

0 payments

Through program year 2024, $12,525,608 in general payments and $0 in research payments were reported against Arexvy (Respiratory).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2024 General $6,280,960 97,290
2023 General $6,244,649 94,905

Breakdown

Who paid General payments · program years 2023–2024
  1. GlaxoSmithKline, LLC. $12,525,608 192,195 payments
Top recipients General payments · program year 2024
  1. William Frazier Pulmonary Disease · Canton, MS $106,570 2% · 83 payments
  2. Joseph Boscia Pulmonary Disease · Spartanburg, SC $105,076 2% · 64 payments
  3. Jacqueline Eghrari-Sabet Allergy & Immunology · Vienna, VA $104,282 2% · 87 payments
  4. Robert Sussman Summit, NJ $101,379 2% · 85 payments
  5. Michael Ott Pulmonary Disease · Eglin Afb, FL $99,095 2% · 125 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2024.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2024
  1. Pulmonary Disease Internal Medicine $2,721,345 45% · 2,327 practitioners
  2. Family Medicine $726,802 12% · 10,616 practitioners
  3. Internal Medicine $494,895 8% · 7,517 practitioners
  4. Allergy & Immunology $353,452 6% · 766 practitioners
  5. Nurse Practitioner, Family Nurse Practitioner $350,228 6% · 7,257 practitioners

The top 5 of 160 specialties; each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2024
  1. Texas $727,503 12% · 4,021 recipients
  2. California $709,501 11% · 3,603 recipients
  3. Florida $665,038 11% · 3,254 recipients
  4. New York $476,381 8% · 2,384 recipients
  5. Pennsylvania $339,197 5% · 1,836 recipients

The top 5 of 53 states; each share is of general payments naming this product in 2024 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

2,698,120

Prescriptions dispensed, refills included

Drug cost

$736,054,033

Paid at the pharmacy, in all

Prescribers

25,157

With 11 or more claims of it

Medicare Part D drugs matched to AREXVY, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Arexvy Rsvpref3 Antigen/As01e/Pf Same name 25,157 2,698,120 $736,054,033

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Armaghan Azad Emergency Medicine CA 182,500 $48,623,837 None on record
Cedric Davis Family Practice IL 134,247 $34,211,953 None on record
Eldridge Burns Family Practice NE 63,932 $16,494,399 None on record
Daniel Bauer Internal Medicine NC 63,048 $16,774,403 None on record
Shaun Gill Hospitalist PA 61,658 $17,495,576 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron
192,195 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record